Atiny stent with a power to give your life back

Bi-VERVE® Stent system

For thousands of years we have administered drugs to treat body's ailments

Nervous system

Superhighway controls everything \checkmark Trigger \checkmark Production of proteins/ molecules Immune response \checkmark Inflammation of joints/organs







Imagine the potential to directly control and modify the flow of traffic through this superhighway.....

As simple as that.....





Fluoroscopic guidance

Peripheral vein cannulation

Guidewire-catheter assembly



Reach intended target

Unfold the stent construct

Repositionable and retrievable



Patented technology

Electroactive construct

Battery

Electronics for sensing and stimulation



Jugular vein

Vagus Carotid nerve artery

Vagus nerve stimulation







Neurovascular bundle

Transmit stent

Receive stent



Transmit stent

Receive stent





A Band-Aid and 30 minutes is all that is needed to rebuild your life back!











FDA: Technology de-risk

New device: non inferiority PMA process

Market: Application



A major breakthrough to stimulate biological circuits



Biverv®



Extensive animal validity data



Multi-site pacing and sensing



Easy delivery and deployment



AI backed control



Battery life: up to 5 years



Scale: 2 mm upwards









Winning team

Advisory board

Team (Investment and legal)

Finance and investing: John Visconti, Visconti and Associates

Corporate legal team: Rachana Khanna, RK Law group, CT

Iqbal Ishar,

Ishar Law, NY



Team (Engineering and R/D & Regulatory)

Jin Park

VP, Research and development

More than 25 years experience in stent design, formerly at Cordis

Daniel Olsen

Director, Quality assurance & production

More than 20 years experience in medical device development and Quality assurance and production

Egemen Tuzun

FDA Regulatory affairs

More than 20 years experience in PMA approval and pre-FDA GLP studies.



Scientific Advisory Board (Represents multiple specialties)

Neurovascular Surgery/ Neurosurgery Neurologists Vascular Surgeons Interventional radiologists Rheumatologists Immunologists





Market size

McKinsey & Co

By 2025 ~ 2 million patients in G-7 with severe arthritis/Crohn's

Biologics (pharmaceuticals) cost:\$ 20,000 per patient per year

But patients eventually become resistant to medications

If we consider only 5% market penetration with bioelectric implants

Conservative market size of

~ \$ 2 billion per year

Milestones



Biverv®

A tiny scaffold to rebuild your life!

